Health
Drug From Bowel Bacteria Helps Blood Cancer Patients Facing Deadly Complication
- MaaT Pharma surges 24% after positive clinical-trial results
- New therapy poised as first microbiome therapy for cancer
This article is for subscribers only.
When Anne Maldzinski underwent a blood stem-cell transplant to cure her cancer, the procedure triggered a life-threatening immune reaction that ravaged her intestines, leaving her survival dependent on a surprising treatment: human feces.
After multiple immune-suppressive drugs failed to control the symptoms of graft-versus-host disease — a common complication for donor bone marrow recipients — Maldzinski was given an experimental therapy developed by French biotech MaaT Pharma through an early access program. The effect was dramatic.